Back to News
Market Impact: 0.25
One04 Therapeutics launches on encouraging CPV-104 Phase 1 interim results and plans to expand clinical development to include kidney diseases and dry AMD
Source: GlobeNewswire
Healthcare & BiotechProduct LaunchesCorporate Guidance & Outlook
One04 Therapeutics launched following encouraging interim Phase 1 results for CPV-104. The company plans to broaden clinical development into kidney diseases and dry age-related macular degeneration, expanding the potential addressable patient population. The update is an early-stage clinical and pipeline-positive catalyst, although efficacy and safety details were not disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
More News
- Grab aims for 'next level' in financial services with purchase of buy-now pay-later platform Atome
- Is Amazon Stock a Buy After Its Best Quarter in Years?
- Push for AI regulation mounts as talk of AI’s ‘existential’ risks go mainstream. But Trump resists calls for a slowdown
- Wells Fargo sees improvement in a key metric — plus, Lilly gets praise beyond GLP-1s
- Beta Bionics prices $150M public offering at $17.25/share
- Why Dave & Buster's Stock Tumbled Today